Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C

Hepatology

Volumn 27, Issue 5, 1998, Pages 1394-1402

  Kasahara, Akinori ^e   Hayashi, Norio ^a   Mochizuki, Kiyoshi ^a   Takayanagi, Masahide ^e   Yoshioka, Kentaro ^e   Kakumu, Shinichi ^b   Iijima, Akihiro ^e   Urushihara, Akihiko ^e   Kiyosawa, Kendo ^c   Okuda, Michiari ^e   Hino, Keisuke ^e   Okita, Klwamu ^d  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d YAMAGUCHI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; BETA INTERFERON; INTERFERON; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON;

ADULT; ARTICLE; CANCER INCIDENCE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED STUDY; ECHOGRAPHY; FEMALE; HEPATITIS C; HUMAN; HUMAN TISSUE; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LIVER BIOPSY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

ADULT; AGE FACTORS; ALANINE TRANSAMINASE; CARCINOMA, HEPATOCELLULAR; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; INTERFERON-BETA; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; RISK FACTORS; RNA, VIRAL; SEX FACTORS;

EID: 17344369924     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.510270529     Document Type: Article

References (18)

1. Di Bisceglie AM, Goodman ZD, Ishak KG, Hoofnagle JH, Melpolder JJ, Alter HJ. Long-term clinical and histological follow-up of chronic posttransfusion hepatitis. HEPATOLOGY 1991;14:969-974.
2. Kiyosawa K, Sodeyama T, Tanaka E, Gibo Y, Yoshizawa K, Nagano Y, Furuta S et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma. Analysis by detection of antibody to hepatitis C virus. HEPATOLOGY 1990;12:671-675.
3. Takano S, Yokosuka O, Imazeki F, Tagawa M, Omata M. Incidence of hepatocellular carcinoma in chronic hepatitis B and C. A prospective study of 251 patients. HEPATOLOGY 1995;21:650-655.
4. Ikeda K, Saitoh S, Koida I, Arase Y, Tsubota A, Chayama K, Kumada H, et al. A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. HEPATOLOGY 1993;18:47-53.
5. Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, Nevens E Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997;112:463-472.
6. Oka H, Kurioka N, Kim K, Kanno T, Kuroki T, Mizoguchi Y, Kobayashi K. Prospective study of early detection of hepatocellular carcinoma in patients with cirrhosis. HEPATOLOGY 1990;12:680-687.
7. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC, Rerrilo RP, Carey W, et al. Treatment of chronic hepatitis C with recombinant interferon alpha. A multicenter randomized controlled trial. N Engl J Med 1989;321:1501-1506.
8. Di Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J, Goodman Z, et al. Recombinant interferon alpha therapy for chronic hepatitis C. A randomized, double blind placebo-controlled trial. N Engl J Med 1989;321:1506-1510.
9. Hagiwara H, Hayashi N, Mita E, Ueda K, Takehara T, Kasahara A, Fusamoto H, et al. Detection of hepatitis C virus RNA in serum of patients with chronic hepatitis C treated with interferon-α. HEPATOLOGY 1992;15:37-41.
10. Hagiwara H, Hayashi N, Mita E, Takehara T, Kasahara A, Fusamoto H, Kamada T. Quantitative analysis of hepatitis C virus RNA in serum during interferon alfa therapy. Gastroenterology 1993;104:877-883.
11. Kasahara A, Hayashi N, Hiramatsu N, Oshita M, Hagiwara H, Katayama K, Kato M, et al. Ability of prolonged interferon treatment to suppress relapse after cessation of therapy in patients with chronic hepatitis C: a multicenter randomized controlled trial. HEPATOLOGY 1995;21:291-297.
12. Hiramatsu N, Hayashi N, Kasahara A, Hagiwara H, Takehara T, Haruna Y, Naito M, et al. Improvement of liver fibrosis in chronic hepatitis C patients treated with natural interferon alpha. J Hepatol 1995;22:135-142.
13. Shindo M, Di Bisceglie AM, Hoofnagle JH. Long-term follow-up of patients with chronic hepatitis C treated with α-interferon. HEPATOLOGY 1992;15:1013-1016.
14. Hagiwara H, Hayashi N, Kasahara A, Oshita M, Katayama K, Naito M, Masuzawa M, et al. Long-term biochemical and virological response to natural interferon-a in patients with chronic hepatitis C. Dig Dis Sci 1996;41:1001-1007.
15. Hagiwara H, Hayashi N, Kasahara A, Oshita M, Katayama K, Kato M, Masuzawa M, et al. Treatment with recombinant interferon-α2a for patients with chronic hepatitis C: predictive factors for biochemical and virologie response. Scand J Gastroenterol 1996;31:1021-1026.
16. Kuzushita N, Hayashi N, Katayama K, Kanto T, Oshita M, Hagiwara H, Kasahara A, et al. High levels of serum interleukin-10 are associated with a poor response to interferon treatment in patients with chronic hepatitis C. Scand J Gastroenterol 1997;32:169-174.
17. Kasahara A, Hayashi N, Mochizuki K, Oshita M, Katayama K, Kato M, Masuzawa M, et al. Circulating matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 as serum markers of fibrosis in patients with chronic hepatitis C. Relationship to interferon response. J Hepatol 1997;26:574-583.
18. Yuki N, Hayashi N, Kasahara A, Hagiwara H, Takehara T, Oshita M, Katayama K, et al. Pretreatment viral load and response to prolonged interferon-α course for chronic hepatitis C. I Hepatol 1995;22:457-463.